Sermonix Pharmaceuticals @SermonixPharma

Currently studying investigational oral lasofoxifene for the treatment of locally advanced or metastatic ER+/HER2- breast cancer harboring an ESR1 mutation(s). sermonixpharma.com Joined June 2022
  • Tweets
    91
  • Followers
    67
  • Following
    10
  • Likes
    9